BVF II GP LLC
CIK 1803806 · last filed 2026-07-16
BVF II GP LLC is a corporate insider who has filed 11 SEC Form 4 insider transactions across 8 companies since 2020. The most recent filing, for XOMA, was dated Jul 16, 2026. Across all open-market trades the lifetime net is −$2.54B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $86.4M across reported positions. The firm reports its address in San Francisco, CA. 159 SEC filings were submitted jointly with BVF GP HOLDINGS LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$86.43M
8
11
-$2.54B
Filer Profile
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 0 | $40.17 | $0 | $1.42M | 2 | 2026-07-16 |
| KYMR | Director | 484,057 | $111.95 | $54.19M | $0 | 1 | 2026-06-25 |
| XOMA Royalty Corp (XOMAP) Delisted | Director | 0 | $24.98 | $0 | -$159.93M | 2 | 2025-01-28 |
| OLMA | Director | 3,684,068 | $8.75 | $32.24M | $0 | 1 | 2024-06-18 |
| RAIN | Director | 0 | $1.00 | $0 | $0 | 1 | 2024-01-29 |
| POINT Biopharma Global Inc. (PNT) Delisted | 0 | $12.50 | $0 | -$2.14B | 1 | 2023-12-20 | |
| CTI BIOPHARMA CORP (CTIC) Delisted | Director | 2,228,652 | $9.09 | $20.26M | $0 | 2 | 2023-04-07 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 5,663,912 | $0.04 | $253.2K | -$242.06M | 1 | 2021-01-26 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-16 | XOMA Royalty Corp (XOMA) Delisted | U | −75,933,030 | $0 | EDGAR |
| 2026-06-25 | KYMR | Grant (A) | — | $0 | EDGAR |
| 2025-01-28 | XOMA Royalty Corp (XOMAP) Delisted | Sell (S) | −6,507,170 | -$169.84M | EDGAR |
| 2024-06-18 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2024-01-29 | RAIN | Mixed | −85,768,030 | $0 | EDGAR |
| 2023-12-20 | POINT Biopharma Global Inc. (PNT) Delisted | Sell (S) | −171,612,780 | -$2.14B | EDGAR |
| 2023-04-07 | CTI BIOPHARMA CORP (CTIC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-09-16 | XOMA Royalty Corp (XOMAP) Delisted | Buy (P) | +563,090 | $9.91M | EDGAR |
| 2021-01-26 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Sell (S) | −58,485,200 | -$242.06M | EDGAR |
| 2020-03-27 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +82,640 | $1.42M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.